This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turpin, J. A.
Right arrow Articles by Rice, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turpin, J. A.
Right arrow Articles by Rice, W. G.

 Previous Article  |  Next Article 

J. Virol., Sep 1996, 6180-6189, Vol 70, No. 9
Copyright © 1996, American Society for Microbiology

Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles

JA Turpin, SJ Terpening, CA Schaeffer, G Yu, CJ Glover, RL Felsted, EA Sausville and WG Rice
Laboratory of Antiviral Drug Mechanisms, National Cancer Institute- Frederick Cancer Research and Development Center, SAIC Frederick, Maryland 21702, USA.

The Cys-Xaa2-Cys-Xaa4-His-Xaa4-Cys zinc fingers of retroviral nucleocapsid proteins are prime antiviral targets because of conservation of the Cys and His chelating residues and the absolute requirement of these fingers in both early and late phases of retroviral replication. We previously reported that certain disulfide- substituted benzamides (DIBAs) chemically modify the Cys residues of the fingers, resulting in inhibition of human immunodeficiency virus type 1 (HIV-1) replication (W. G. Rice, J. G. Supko, L. Malspeis, R. W. Buckheit, Jr., D. Clanton, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. Bader, S. M. Halliday, L. Coren, R. C. Sowder II, L. O. Arthur, and L. E. Henderson, Science 270:1194-1197, 1995). We now examine the consequences of the interaction of DIBAs with the zinc fingers of the HIV-1 p7 nucleocapsid protein and its Pr55gag precursor. In HIV-1-infected U1 cells, DIBAs inhibited the release of infectious virions, and even under conditions in which virion particles were produced, the particles were noninfectious. DIBAs caused abnormal processing of Gag precursors, and the inhibitory effect on processing was not due to inhibition of the HIV-1 protease enzyme or Pr55gag myristoylation. Rather, the defect in processing was due to the formation of intermolecular cross-linkages among the zinc fingers of adjacent Gag molecules, rendering the precursors no longer recognizable by HIV-1 protease. Likewise, DIBAs caused intermolecular cross-linkage among recombinant Pr55gag packaged into pseudovirions, thereby generating modified precursors that were resistant to the action of protease. Thus, DIBAs chemically modified the mutationally intolerant retroviral zinc fingers in infected cells, interrupting protease-mediated maturation of virions and leading ultimately to the production of compromised virions.


This article has been cited by other articles:

  • Wallace, G. S., Cheng-Mayer, C., Schito, M. L., Fletcher, P., Miller Jenkins, L. M., Hayashi, R., Neurath, A. R., Appella, E., Shattock, R. J. (2009). Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibitors Impede trans Infection in Cellular and Explant Models and Protect Nonhuman Primates from Infection. J. Virol. 83: 9175-9182 [Abstract] [Full Text]  
  • Nichols, M. (2007). The Fight Against Tamoxifen Resistance in Breast Cancer Therapy: A New Target in the Battle?. Mol. Interv. 7: 13-16 [Abstract] [Full Text]  
  • Campbell, S., Oshima, M., Mirro, J., Nagashima, K., Rein, A. (2002). Reversal by Dithiothreitol Treatment of the Block in Murine Leukemia Virus Maturation Induced by Disulfide Cross-Linking. J. Virol. 76: 10050-10055 [Abstract] [Full Text]  
  • Mocchegiani, E., Muzzioli, M. (2000). Therapeutic Application of Zinc in Human Immunodeficiency Virus against Opportunistic Infections. J. Nutr. 130: 1424S-1431 [Abstract] [Full Text]  
  • Berthoux, L., Péchoux, C., Darlix, J.-L. (1999). Multiple Effects of an Anti-Human Immunodeficiency Virus Nucleocapsid Inhibitor on Virus Morphology and Replication. J. Virol. 73: 10000-10009 [Abstract] [Full Text]  
  • Druillennec, S., Dong, C. Z., Escaich, S., Gresh, N., Bousseau, A., Roques, B. P., Fournie-Zaluski, M. C. (1999). A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity. Proc. Natl. Acad. Sci. USA 96: 4886-4891 [Abstract] [Full Text]  
  • Turpin, J. A., Buckheit, R. W. Jr., Derse, D., Hollingshead, M., Williamson, K., Palamone, C., Osterling, M. C., Hill, S. A., Graham, L., Schaeffer, C. A., Bu, M., Huang, M., Cholody, W. M., Michejda, C. J., Rice, W. G. (1998). Inhibition of Acute-, Latent-, and Chronic-Phase Human Immunodeficiency Virus Type 1 (HIV-1) Replication by a Bistriazoloacridone Analog That Selectively Inhibits HIV-1 Transcription. Antimicrob. Agents Chemother. 42: 487-494 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»